Surprise as Amgen pips Regeneron/Sanofi to first PCSK9 inhibitor approval
This article was originally published in Scrip
While all eyes were on the US market, Amgen has clinched victory over Regeneron/Sanofi in the race to be first to approval with a PCSK9 inhibitor in another major territory, the EU.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.